Protego Biopharma is leading the way in the revolutionary field of drug discovery, specifically targeting protein misfolding diseases. Just as natural forces shape the picturesque Torrey Pines Beach landscape, Protego understands that protein folding and misfolding are heavily influenced by physical and cellular forces. Using a combination of monogenic and pathway genetic evidence, bioinformatics, deep biology, and clinical path analysis, Protego identifies high-confidence targets for unmet medical needs.

Their innovative discovery platform focuses on disease-modifying approaches, developing a pharmacological chaperone screening platform tailored to each disease target. By anchoring on protein stability and utilizing phenotypic and functionality readouts, Protego addresses disease defects directly. Protego's translational research aims to identify specific and sensitive biomarkers, enabling early patient identification, clinical stage readouts in target engagement, and therapeutic efficacy.

With a primary focus on systemic amyloid diseases like light chain (LC) amyloidosis, Protego also targets other monogenetic protein misfolding diseases that lead to conditions such as myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Supported by a proven team, Protego Biopharma collaborates with world-class investors and partners who share their mission. They continue to build upon the success of tafamidis, a pharmacological chaperone approach for transthyretin amyloidosis, discovered and developed by their cofounders, Dr.

Jeffery W. Kelly and Dr. Richard Labaudinière.

Find out more about Protego's groundbreaking work in protein folding and misfolding by visiting their website. They are also actively seeking passionate and motivated individuals to join their team in making impactful discoveries that can improve people's health